Wall Street Outlook on Eli Lilly Stock Performance and Future Growth
Yahoo Finance ·
Eli Lilly has delivered remarkable long-term returns, soaring 410 percent over the past five years and 58 percent over the past 52 weeks. Yet, its momentum has cooled in 2026 with a modest 10.1 percent gain, lagging behind the S&P 500's 12.5 percent rise. This recent deceleration likely stems from stretched valuations following years of outperformance, with the trailing price-to-earnings ratio sitting near 40. Still, the company boasts the world's best-selling medication. In the third quarter of 2025, its dual GLP-1 receptor agonist, tirzepatide, surpassed Merck's Keytruda to become the top-selling drug globally. Marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, tirzepatide anchors massive industry potential. Morgan Stanley projects the GLP-1 sector will reach 190 billion dollars by 2045, more than doubling 2025 levels, driven by upcoming oral treatments and broader U.S. Medicare coverage.
AI 시장 분석
Eli Lilly's stock surged 410% over the past 5 years, but has risen only 10.1% this year, underperforming the S&P 500. While a P/E ratio around 40 creates valuation pressure, its flagship obesity drug tirzepatide continues its growth by becoming the world's top-selling drug. Morgan Stanley projects the GLP-1 market to reach $190 billion by 2045, signaling further growth.
상승 영향
- Biotechnology — Strong sales of Eli Lilly's GLP-1 treatments and the projected $190 billion market size by 2045 are expected to drive growth across the pharmaceutical and biotech sectors.
DYAX 전담 분석
Eli Lilly's tirzepatide (Mounjaro, Zepbound) surpassing Merck's Keytruda to become the world's top-selling drug is a core driver of earnings growth. Morgan Stanley's upward revision of its forecast by $40 billion, fueled by the launch of oral treatments and expanded US Medicare coverage, provides a basis for future corporate value revaluation.
Despite valuation burdens, expectations for long-term market expansion remain valid. The bullish scenario expects a stock price rebound through market share expansion, while the possibility of short-term corrections due to overvaluation controversies also persists. Investors should closely monitor upcoming earnings releases and the pace of expanded US health insurance coverage.
AI가 생성한 분석으로 투자 자문이 아닙니다.
DYAX Investor Sentiment
Bullish (Long) 45% · Bearish (Short) 55%
402 participants
Related News
- IonQ Secures Nvidia Partnership Less Than Two Years After Jensen Huang's Quantum Warning
- Is It Too Late to Buy GE Vernova After Its 45% Gain in 2026?
- Google, OpenAI, and Anthropic Take Major Steps Toward AI Safety
- 1 Agentic AI Chip Stock to Buy and 1 to Sell
- Two High-Yield Monthly Dividend Stocks Exceeding 6% That I Hold
- Fastly Gains Attention on AI Traffic and Meta Muse Integration
